Accenture and Salesforce have announced they are investing in the development of Salesforce Life Sciences Cloud to help life science companies create sustainable value and drive growth through innovations, assets and accelerators, powered by data and AI.
Building on their recently announced generative AI collaboration, the companies will leverage their joint GenAI acceleration hub to develop new solutions and use cases for Salesforce Life Sciences Cloud. They will use Salesforce Data Cloud and Salesforce’s Einstein AI to help increase productivity and transform healthcare professional and patient experiences.
Emma McGuigan, senior managing director and enterprise and industry technologies lead at Accenture, said: “The rapid pace of science and technology advancements is making treatment decisions more complex.
“Data and AI will drive differentiation around how life science organizations engage with their customers. Together with Salesforce, we can help organizations establish a digital foundation to support omni-channel experiences across sales, service and marketing with data and intelligence at the core.”
The rapid adoption of data and analytics capabilities to fuel decisions and operations has become a top investment priority for 58 percent of life sciences companies, according to Accenture Research.
Amit Khanna, SVP and GM of health and life sciences at Salesforce, said: “Accenture’s deep understanding of the pharma and medtech spaces and their current work to transform patient experiences will help us create innovation for life science companies and in the new development of Salesforce Life Sciences Cloud.”
The duo has also worked with Cencora (formerly AmerisourceBergen), a global pharmaceutical solutions company that offers integrated support, including patient services, across the pharmaceutical development and commercialization journey.
This time, using its Life Sciences Cloud, the companies are set to help Cencora use rich data and insights to modernize patient engagement with a digital-first capability at scale.
Shannon Coven, senior vice president of data and platforms for global pharma services at Cencora, said: “Cencora is committed to leveraging new and emerging technologies, like generative AI, to deliver solutions that reduce potential barriers along the treatment journey and meet the needs of our biopharma partners, healthcare providers and the patients they serve.
“Together with Accenture and Salesforce, we are harnessing the power of data and AI to help improve outcomes and enhance the patient care experience.”
Together, Accenture and Salesforce have already developed assets and accelerators including a patient services Health Cloud assessment framework, which evaluates legacy pharma patient services and a pharmaceutical Data Cloud and Einstein AI accelerator, which provides a holistic view of provider and patient data, using the power of GenAI.
